Oppenheimer initiated coverage on Adverum Biotech with a new price target

6/25/24 8:10:21 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Oppenheimer initiated coverage of Adverum Biotech with a rating of Outperform and set a new price target of $25.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ADVM

Date	Price Target	Rating	Analyst
6/25/2024	$25.00	Outperform	Oppenheimer
4/30/2024	$30.00	Buy	H.C. Wainwright
7/7/2022	$4.00	Hold → Buy	Truist
7/23/2021		Hold → Neutral	Cantor Fitzgerald
7/23/2021	$23.00 → $3.00	Overweight → Neutral	Cantor Fitzgerald
7/23/2021	$5.00 → $2.00	Market Perform	SVB Leerink